The Future of Lymphedema: Potential Therapeutic Targets for Treatment

被引：19

作者：

Brown, Stav ^{[1
]}

Campbell, Adana C. ^{[1
]}

Kuonqui, Kevin ^{[1
]}

Sarker, Ananta ^{[1
]}

Park, Hyeung Ju ^{[1
]}

Shin, Jinyeon ^{[1
]}

Kataru, Raghu P. ^{[1
]}

Coriddi, Michelle ^{[1
]}

Dayan, Joseph H. ^{[1
]}

Mehrara, Babak J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Plast & Reconstruct Surg Serv, 1275 York Ave, New York, NY 10065 USA

来源：

CURRENT BREAST CANCER REPORTS | 2023年 / 15卷 / 03期

关键词：

Lymphedema; TH2; cells; CD4+; VEGF-C; TGFB; Non-steroidal anti-inflammatory drugs; NSAID; Doxycycline; Tacrolimus; ACE inhibitors; Captopril; Pirfenidone; Tetracyclines; Vascular endothelial growth factor C; QUALITY-OF-LIFE; HEPATOCYTE GROWTH-FACTOR; BREAST-CANCER; VEGF-C; LYMPHATIC REGENERATION; GENE-THERAPY; RAT MODEL; LYMPHANGIOGENESIS; FIBROSIS; DOXYCYCLINE;

D O I：

10.1007/s12609-023-00491-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewThis review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.Recent FindingsLymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.

引用

页码：233 / 241

页数：9

共 116 条

[61] Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema [J].